Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282922409> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4282922409 endingPage "31S" @default.
- W4282922409 startingPage "31S" @default.
- W4282922409 abstract "INTRODUCTION: Iron-deficiency anemia is common in women with uterine fibroid (UF)-related heavy menstrual bleeding. Severe anemia is defined as hemoglobin (Hb) levels <10g/dL. The effect of linzagolix, an oral GnRH antagonist, on UF-related severe anemia was assessed in two Phase 3 trials. METHODS: PRIMROSE 1 and 2 are randomized, double-blind, placebo-controlled Phase 3 trials investigating the efficacy and safety of linzagolix 100 mg and 200 mg once daily, with or without hormonal add-back therapy (ABT) in the treatment of UF. Subjects were considered responders if an increase of ≥2g/dL from baseline was achieved. Patients with severe anemia were given iron supplements until they reached the Hb levels >12g/dL. RESULTS: In PRIMROSE 1, of 165 subjects with severe anemia, 57.9%, 61.5%, 82.1% and 65.2% of patients were responders at 24 weeks, in the respective treatment groups (100 mg, 100 mg+ABT, 200 mg and 200 mg+ABT), compared to 50% in the placebo group. In PRIMROSE 2, of 93 patients with severe anemia, 62.5%, 75%, 60% and 73.7%, respectively, were responders, compared to 46.2% for placebo. Given the small sample sizes, statistical significance was not reached. Improvements were maintained at week 52: in PRIMROSE 1, 69.2%, 62.5%, 81.3% and 75% of patients were responders in the respective treatment groups, compared to 40% in placebo, in PRIMROSE 2, 66.7%, 100%, 80%, 87% were responders, respectively. CONCLUSION: High and low doses of linzagolix improved Hb levels in patients with UF suffering from severe anemia." @default.
- W4282922409 created "2022-06-16" @default.
- W4282922409 creator A5003343672 @default.
- W4282922409 creator A5003848425 @default.
- W4282922409 creator A5005951877 @default.
- W4282922409 creator A5023340631 @default.
- W4282922409 creator A5050428416 @default.
- W4282922409 creator A5052083049 @default.
- W4282922409 date "2022-05-01" @default.
- W4282922409 modified "2023-10-18" @default.
- W4282922409 title "Effect of the Oral GnRH Antagonist Linzagolix on Uterine Fibroid-Related Severe Anemia [A105]" @default.
- W4282922409 doi "https://doi.org/10.1097/01.aog.0000826740.25400.f2" @default.
- W4282922409 hasPublicationYear "2022" @default.
- W4282922409 type Work @default.
- W4282922409 citedByCount "0" @default.
- W4282922409 crossrefType "journal-article" @default.
- W4282922409 hasAuthorship W4282922409A5003343672 @default.
- W4282922409 hasAuthorship W4282922409A5003848425 @default.
- W4282922409 hasAuthorship W4282922409A5005951877 @default.
- W4282922409 hasAuthorship W4282922409A5023340631 @default.
- W4282922409 hasAuthorship W4282922409A5050428416 @default.
- W4282922409 hasAuthorship W4282922409A5052083049 @default.
- W4282922409 hasConcept C126322002 @default.
- W4282922409 hasConcept C141071460 @default.
- W4282922409 hasConcept C142724271 @default.
- W4282922409 hasConcept C168563851 @default.
- W4282922409 hasConcept C204787440 @default.
- W4282922409 hasConcept C27081682 @default.
- W4282922409 hasConcept C2776732101 @default.
- W4282922409 hasConcept C2778248108 @default.
- W4282922409 hasConcept C2778917026 @default.
- W4282922409 hasConcept C65409693 @default.
- W4282922409 hasConcept C71924100 @default.
- W4282922409 hasConcept C90924648 @default.
- W4282922409 hasConceptScore W4282922409C126322002 @default.
- W4282922409 hasConceptScore W4282922409C141071460 @default.
- W4282922409 hasConceptScore W4282922409C142724271 @default.
- W4282922409 hasConceptScore W4282922409C168563851 @default.
- W4282922409 hasConceptScore W4282922409C204787440 @default.
- W4282922409 hasConceptScore W4282922409C27081682 @default.
- W4282922409 hasConceptScore W4282922409C2776732101 @default.
- W4282922409 hasConceptScore W4282922409C2778248108 @default.
- W4282922409 hasConceptScore W4282922409C2778917026 @default.
- W4282922409 hasConceptScore W4282922409C65409693 @default.
- W4282922409 hasConceptScore W4282922409C71924100 @default.
- W4282922409 hasConceptScore W4282922409C90924648 @default.
- W4282922409 hasIssue "1" @default.
- W4282922409 hasLocation W42829224091 @default.
- W4282922409 hasOpenAccess W4282922409 @default.
- W4282922409 hasPrimaryLocation W42829224091 @default.
- W4282922409 hasRelatedWork W1540827075 @default.
- W4282922409 hasRelatedWork W1957959321 @default.
- W4282922409 hasRelatedWork W1972032826 @default.
- W4282922409 hasRelatedWork W22040025 @default.
- W4282922409 hasRelatedWork W2216015926 @default.
- W4282922409 hasRelatedWork W2386063442 @default.
- W4282922409 hasRelatedWork W2563828956 @default.
- W4282922409 hasRelatedWork W2963035613 @default.
- W4282922409 hasRelatedWork W3030683988 @default.
- W4282922409 hasRelatedWork W4293548491 @default.
- W4282922409 hasVolume "139" @default.
- W4282922409 isParatext "false" @default.
- W4282922409 isRetracted "false" @default.
- W4282922409 workType "article" @default.